Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Nadda undergoes angioplasty at AIIMS Delhi; currently stable: Hospital

Union Health and Family Welfare Minister JP Nadda underwent angioplasty at AIIMS, Delhi, on August 17 and is currently stable and under observation in the Department of Cardiology.

Nadda undergoes angioplasty at AIIMS Delhi; currently stable: Hospital

On August 17, 2026, Union Health Minister JP Nadda underwent a successful angioplasty procedure at the prestigious All India Institute of Medical Sciences (AIIMS) in New Delhi. According to an official statement by the hospital, the Minister is currently stable and being closely observed in the Department of Cardiology.

An angioplasty is a medical procedure that involves widening narrowed or blocked heart arteries using a thin tube (catheter) equipped with a balloon. Following the inflation of the balloon, a stent is often inserted to keep the artery open and prevent the blockage from recurring.

The Minister's health condition was reported to be stable following the procedure, though it is noted that full recovery and normalcy will take time. Earlier this week, Nadda had been admitted to AIIMS on August 13 after experiencing unease in the evening. Following a series of tests, including a coronary angiography, he was deemed suitable for the angioplasty.

The angiography was performed to detect any blockages in the heart's arteries and assess the extent of obstruction in each artery. Based on the results, it was determined that the procedure was necessary, either via stent placement or medication, to restore proper blood flow.

Written by urgent.news from Free Press Journal's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

This story

This is one outlet's version. Read the fullest account.

Read the original at health.economictimes.indiatimes.com →

More in Health & Medicine

LG Chem Begins Preclinical Development of Genuv’s Next-Generation Immuno-Oncology Candidate

LG Chem is moving ahead with the development of GNV205, a next-generation immuno-oncology candidate licensed from South Korean biotech company Genuv, as it seeks to strengthen its pipeline of…

  • LG Chem starts preclinical studies for GNV205, a next-gen immuno-oncology drug.
  • GNV205 combines PD-1 antibody with interleukin-2 for targeted immune response.
  • LG Chem acquired exclusive rights to GNV205 in September 2025.

More from Wednesday 19 August →